Relovair COPD and asthma filings on track despite more mixed trial results – The Pharma Letter


Proactive Investors USA & Canada

Relovair COPD and asthma filings on track despite more mixed trial results
The Pharma Letter
For asthma, the company plans to file for approval in Europe in mid-2012 and will continue discussions with the US Food and Drug Administration on the regulatory requirements for a US asthma indication. GSK is looking to replace its top-selling drug
Relovair on track for filing in mid-2012, says GSKPMLiVE
GSK, Theravance Report Mixed Bag of Data for Relovair in COPD, AsthmaGenetic Engineering News
GSK and Theravance Announce Completion of the Relovair(TM)* Registrational MarketWatch (press release)
Reuters –MedCity News –FierceBiotech
all 36 news articles »

View full post on asthma – Google News

GSK, Theravance Report Mixed-Bag of Data for Relovair in COPD, Asthma – Genetic Engineering News

GSK, Theravance Report Mixed-Bag of Data for Relovair in COPD, Asthma
Genetic Engineering News
GlaxoSmithKline (GSK) and Theravance are reporting mostly positive results from two studies for Relovair in chronic obstructive pulmonary disease (COPD) and asthma. Relovair met its primary endpoint in one of two replicate studies in COPD comparing it
GSK and Theravance Announce Completion of the Relovair(TM)* Registrational MarketWatch (press release)
GSK lung drug has mixed results but filing on trackReuters
GSK's Relovair on track for COPD drug filing; talks on asthma in US ongoingMedCity News
FierceBiotech –4-traders
all 28 news articles »

View full post on asthma – Google News

GSK, Theravance report completion of Relovair studies in COPD and asthma – Pharmaceutical Business Review


Visit Bulgaria

GSK, Theravance report completion of Relovair studies in COPD and asthma
Pharmaceutical Business Review
GlaxoSmithKline (GSK) and Theravance have announced the completion of the phase III registration programme for the once-daily investigational medicine Relovair used to treat chronic obstructive pulmonary disease (COPD) and asthma.
GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies MarketWatch (press release)
Theravance Falls Most in 3 Years After Glaxo Drug FailsBusinessWeek
Glaxo on the slide after trials setback for asthma drugEvening Standard
Visit Bulgaria –TheStreet.com –Wall Street Journal (India)
all 64 news articles »

View full post on asthma – Google News

Glaxo set to submit Relovair to regulatory authorities – ShareCast

Glaxo set to submit Relovair to regulatory authorities
ShareCast
Additionally, all but one of the pivotal studies in patients with asthma have been completed. For COPD, Glaxo intends to submit regulatory applications in the US and Europe in mid-2012. For asthma, Glaxo plans to submit an application in Europe in
GSK and Theravance Announce Initial Outcomes From Pivotal Phase III Studies MarketWatch (press release)

all 5 news articles »

View full post on asthma – Google News

GlaxoSmithKline Ties Up Loose Ends With Relovair – Minyanville.com


Minyanville.com

GlaxoSmithKline Ties Up Loose Ends With Relovair
Minyanville.com
The FDA recently made more stringent requirements for drugs that contain long-acting beta agonists for the treatment of asthma due to safety concerns.
Glaxo, Theravance report Relovair safety dataBusinessWeek
GlaxoSmithKline, Theravance Combined Drug for COPD Shows Postitive ResultsFOXBusiness
GSK and Theravance announce combination ICS/LABA Phase II results in the MarketWatch (press release)
Proactive Investors USA & Canada –FierceBiotech –RTT News
all 39 news articles »

View full post on asthma – Google News

Glaxo, Theravance report Relovair safety data – BusinessWeek

Glaxo, Theravance report Relovair safety data
BusinessWeek
GlaxoSmithKline PLC and Theravance Inc. said Wednesday their lung disease and asthma drug Relovair met its goals in a mid-stage safety study.
GSK and Theravance announce combination ICS/LABA Phase II results in the MarketWatch (press release)
GlaxoSmithKline Reports Positive Results For Phase II Trial Of Relovair In RTT News
Theravance Announces Results From Phase II Study For Developmental Combination Stock Markets Review

all 31 news articles »

View full post on asthma – Google News